Document:

EX-10.24

 Exhibit 10.24 

CONFIDENTIAL TREATMENT 
 CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [*], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

SUPPLY AGREEMENT 

THIS SUPPLY AGREEMENT (the “Supply Agreement”) is made effective as of May 27, 2011 (the “Effective Date”) by and
between Gen-Probe Incorporated, a company incorporated under the laws of the State of Delaware (“Gen-Probe”), and Roka Bioscience, Inc., a company incorporated under the laws of the State of Delaware (“Roka”). Roka and Gen-Probe
may hereafter be referred to collectively as the “Parties” and individually as a “Party”. 
 WHEREAS, on
September 10, 2009 Gen-Probe and Roka entered into a series of agreements (the “transaction documents”) pursuant to which Roka acquired certain assets and licenses from Gen-Probe relating to the development, manufacture and
commercialization of certain products in the Company Field (as defined in that certain License Agreement dated September 10, 2009 by and between Roka and Gen-Probe (the “License Agreement”)); and 

WHEREAS, in connection with the transactions contemplated by the License Agreement and the other transaction documents, including without
limitation that certain letter agreement dated September 10, 2009 re: “Panther Supply Terms”, the Parties further contemplated entering into a supply agreement relating to the supply by Gen-Probe to Roka of Gen-Probe’s
integrated, fully-automated low to mid volume molecular diagnostics PantherTM instrument system for Commercialization in the Roka Field (as defined hereinafter). 

NOW THEREFORE, in consideration of the premises of each of the Parties to the other herein contained, and the covenants, promises,
representations and warranties set forth herein, and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged by the Parties), intending to be legally bound hereby, it is mutually agreed as follows:

  

	1.	DEFINITIONS 

 l.1. “Affiliate” means, with respect to any Person, any
Person which, directly or indirectly, controls, is controlled by, or is under common control with, the specified Person. For the purposes of this definition, the term “control”, as applied to any Person, means the possession, directly or
indirectly, of the power to direct or cause the direction of the management of that Person, whether through ownership of voting securities or otherwise. 

1.2. “Applicable Laws” means all laws, ordinances, rules and regulations within the Territory applicable to the Parties’
activities under this Supply Agreement, and the obligations of each Party hereunder as the context requires, including, without limitation, all applicable foreign, federal, state and local laws and regulations of the Territory. 

 1.3. “Business Day” means any day that is not a Saturday, Sunday or other day on
which commercial banks located in the State of New York, or Gen-Probe’s facilities are authorized or required to be closed, as the case may be. 

1.4. “Calendar Quarter” means any of the three-month periods beginning January 1, April 1, July 1 or
October 1 of any calendar year. 
 1.5. “Calendar Year” means the twelve-month period beginning January 1 and
ending December 31. 
 1.6. “Claim” means any claim, action, suit, demand or other legal assertion or proceeding
brought by a Third Party against any of the Roka Indemnified Parties and/or the Gen- Probe Indemnified Parties related to any Losses. 

1.7. “Clinical Diagnostics” means all testing to detect, identify, and/or quantitate one or more nucleic acid sequences for
the purposes of detecting, diagnosing, making prognoses, monitoring, treating, preventing, or studying Human Disease. As used herein, “Human Disease” means any aberration of structure or function of any human cell, tissue or organ, living
or dead. Without limiting the generality of the foregoing, Clinical Diagnostics includes testing in human clinical trials. 
 1.8.
“Commercially Reasonable Efforts” means, with respect to the efforts to be expended by a Party with respect to any objective under this Supply Agreement, reasonable, good-faith efforts to accomplish such objective as such Party
would normally use to accomplish a similar objective under similar circumstances exercising reasonable business judgment. 
 1.9.
“Commercialization”, “Commercialize”, or “Commercializing”, with respect to the Panther Instruments, means any and all activities directed to and including the marketing, promoting, distributing,
leasing, and/or selling of, or otherwise commercially exploiting, the Panther Instruments. 
 1.10. “Confidential
Information” shall have the meaning given to such term in the Confidentiality Agreement. 
 1.11. “Confidentiality
Agreement” means that certain Confidential Disclosure Agreement, effective as of May 13, 2010, by and between Gen-Probe and Roka. 

1.12. ‘‘Forecasted Requirements” and “Forecasts”, with respect to the Panther Instruments, means the
amount of Panther Instruments projected by Roka to be required to meet its or its Affiliates’ requirements during a specific time period in the future. Such projections can be based on standard production planning parameters, including, but not
limited to, sales forecasts, sales demand forecasts, promotional forecasts, inventory requirements, and the like. 
 1.13.
“Gen-Probe Indemnified Parties” means Gen-Probe, Gen-Probe’s Affiliates, any of their successors or assigns, and any of their respective current or former directors, officers, employees, and contract manufacturers. 

  
 -2- 

 1.14. “Industrial Applications” shall have the same meaning as that term is
defined in the License Agreement, except that “Infection Control Applications” shall not be considered part of “Industrial Applications” for purposes of this Supply Agreement 

1.15. “Infection Control Applications” shall have the same meaning as that term is defined in the License Agreement. 

1.16. “Intellectual Property Rights” means, collectively, all of the following intangible legal rights in the Territory,
whether or not filed, perfected, registered or recorded and whether now or hereafter existing, filed, issued or acquired: (i) inventions, patents, patent disclosures, patent rights, including any and all continuations, continuations-in-part,
divisionals, reissues, reexaminations, utility model, industrial designs and design patents or any extensions thereof, (ii) rights associated with works of authorship, including without limitation, copyrights, copyright applications and
copyright registrations, (iii) rights in trademarks, trademark registrations and applications therefor, trade names, service marks, service names, logos, or trade dress, (iv) rights relating to the protection of formulae, trade secrets,
Know-How and Confidential Information, and (v) all other intellectual or proprietary rights in the Territory. 
 1.17.
“Know-How” means any information or material that is confidential and proprietary, including, without limitation, ideas, concepts, discoveries, inventions, developments, improvements, know-how, trade secrets, designs, devices,
equipment, process conditions, algorithms, notation systems, works of authorship, computer programs, technologies, formulas, techniques, methods, procedures, assay systems, applications, data, documentation, reports, chemical compounds, products and
formulations, whether patentable or otherwise. Know-How shall also include non-confidential information and material to the extent such information and material first lost its confidentiality by virtue of its disclosure in an issued patent or
published patent application, a filing with a Regulatory Authority or as part of a legal proceeding. 
 1.18. “Manufacture”
or “Manufacturing”, with respect to the Panther Instruments, means the commercial manufacture, storage, handling, production, and packaging of Panther Instruments pursuant to this Supply Agreement. 

1.19. “Manufacturing Costs”, with respect to the Panther Instruments, means the aggregate actual cost to Gen-Probe to
Manufacture the Panther Instruments, which actual cost shall be comprised of the cost of goods produced as determined in accordance with the definition of Cost of Goods Sold determined in accordance with Generally Accepted Accounting Principles. In
the event that Panther Instruments are purchased by Gen-Probe from a Third Party, Manufacturing Costs shall be equal to the actual costs (including the transfer price, applicable taxes, and costs relating to storage, shipping and handling) paid by
Gen-Probe for such Panther Instruments from time to time. 
 1.20. “NAT” means nucleic acid test or nucleic acid testing,
as the context requires. 
 1.21. “Net Sales” shall mean the aggregate gross invoiced sales by Roka or any of its
Affiliates, licensees or sublicensees to unrelated Third Parties for Panther Instruments and Panther-Related Products, less the following deductions to the extent actually included in the gross invoiced sales price for such Panther Instruments or
Panther-Related Products or otherwise directly paid 

  
 -3- 

 
or incurred by Roka or any of its Affiliates, licensees or sublicensees with respect to the sale of such Panther Instruments or Panther-Related Product: (a) trade, quantity and cash
discounts and rebates allowed to and taken by customers; (b) refunds, chargebacks and any other allowances actually paid to or taken by customers; (c) amounts separately and actually credited to customers for Panther Instrument returns,
credits and allowances; (d) special outbound packing, transportation, freight, handling, postage charges and other charges such as insurance relating thereto that are separately billed to the customer or prepaid; and (e) sales, excise,
value added, turnover, use and other like taxes or customs duties paid and any other governmental charges, excluding net income tax, imposed upon the sale of the Panther Instruments. 

1.22. “Panther Instrument” means the production version (including future versions thereof) of Gen-Probe’s integrated,
fully-automated low to mid volume molecular diagnostics instrument system. The Panther Instrument has been designed for Clinical Diagnostics and was not designed, customized or intended for Industrial Applications. A Panther Instrument, as shipped
to Roka, shall include the Panther analyzer (including the chemi-luminescent detection module), market specific kit, eight sample racks and a computer which allows for the installation of Roka specific assay software. Upgrades for the real-time NAT
detection modules will be made available for purchase by Roka if and when such real-time NAT detection modules are made generally available to Gen-Probe’s customers. The Panther Instrument, as shipped to
Roka, does not include reagent racks, although such reagent racks may be purchased separately by Roka. Panther Instrument software will be provided separately to Roka by Gen-Probe and will need to be installed on each Panther Instrument by an
appropriately trained Roka field service engineer (FSE). 
 1.23. “Panther-Related Products” means any testing services,
assays, assay kits or tests, consumable supplies, and any other product or service sold by Roka for use with Panther Instruments, excluding any service contracts for the maintenance, support or repair of Panther Instruments. 

1.24. “Part(s)” means any field replaceable part required to ensure that a Panther Instrument performs as intended. 

1.25. “Person” means any natural person, corporation, firm, business trust, joint venture, association, organization,
company, partnership or other business entity, or any government, or any agency or political subdivisions thereof. 
 1.26.
“Purchase Order” means a written firm purchase order, specifying the desired quantity of Panther Instruments, delivery dates and delivery instructions. 

1.27. “Roka Field” shall mean the research, development, manufacture, use, distribution, promotion, marketing, offer for
sale, import and export of Panther Instruments and nucleic acid tests and other consumables for use with Panther Instruments, solely for Industrial Applications. For the avoidance of doubt, Roka acknowledges and agrees that for purposes of this
Supply Agreement the Roka Field expressly excludes Infection Control Applications. 

  
 -4- 

 1.28. “Roka Indemnified Parties” means Roka, Roka’s Affiliates, any of
their successors or assigns, and any of their respective current or former directors, officers or employees. 
 1.29.
“Specifications”, with respect to the Panther Instruments, means Gen-Probe’s written specifications for the Panther Instruments, Manufacturing requirements, instructions and
specifications, shipping and storage requirements, and quality control specifications and documentation. The current version of the Specifications are attached hereto as Exhibit A. 

1.30. “Territory” shall mean the world. 

1.31. “Third Party” shall mean any entity other than Gen-Probe or Roka or an Affiliate of Gen-Probe or Roka, as applicable.

 1.32. Other Defined Terms. Each of the following definitions is set forth in the Section of this Supply Agreement indicated below:

  

			
	 Definition
	  	Section
	 2011 Forecast
	  	3.1.1
	 Alliance Manager
	  	4.1
	 Alternative Supplier
	  	8.1
	 Alternative Supplier Notice
	  	8.1
	 Alternative Supplier Triggers
	  	8.1
	 Assay Integration Services
	  	2.4.1
	 Effective Date
	  	Preamble
	 Forecast Start Date
	  	3.1.2
	 Gen-Probe
	  	Preamble
	 Indemnitee
	  	11.3
	 Indemnitor
	  	11.3
	 Initial 2011 Forecast
	  	3.1.1
	 Initial Supply Period
	  	3.1.4
	 Internal Use Instruments
	  	5.15
	 License Agreement
	  	Recitals
	 Losses
	  	11.1
	 Margin Recovery Amount
	  	6.3
	 Roka
	  	Preamble
	 Roka Sequence File
	  	2.4
	 Services Costs
	  	2.4.2
	 Supply Agreement
	  	Preamble
	 Term
	  	9.1
	 Warranty Period
	  	5.3

  
 -5- 

	2.	SUPPLY OF PRODUCTS 

 2.1. Gen-Probe Supply of Products. Subject to the terms and
conditions of this Supply Agreement, and all Applicable Laws, Gen-Probe shall use Commercially Reasonable Efforts to supply, ship and deliver Panther Instruments to Roka or its designee, for Commercialization by Roka exclusively in the Roka Field in
the Territory, in sufficient quantities to meet Roka’s requirements and Forecasts during the Term. Roka shall purchase from Gen-Probe one hundred percent (100%) of its requirements of Panther Instruments for the Territory during the Term.

 2.2. Product Price. Subject to the terms and conditions of this Supply Agreement, Gen-Probe shall supply Panther Instruments to
Roka at a price, for each Panther Instrument, equal to two hundred percent (200%) of the transfer price portion of Gen-Probe’s Manufacturing Cost, plus one hundred percent (100%) of the portion of Gen-Probe’s Manufacturing Cost comprising
applicable taxes and costs relating to storage, shipping and handling, with no additional profit mark-up to Gen-Probe, payable as set forth in Article 6 of this Supply Agreement. Notwithstanding the foregoing, the price for the first 75 Panther
Instruments ordered by Roka hereunder (excluding Internal Use Instruments purchased by Roka under Section 5.15 below) shall equal one hundred fifty percent (150%) of the transfer price portion of Gen-Probe’s Manufacturing Cost, plus one
hundred percent (100%) of the portion of Gen- Probe’s Manufacturing Cost comprising applicable taxes and costs relating to storage, shipping and handling, with no additional profit mark-up to Gen-Probe,
payable as set forth in Article 6 of this Supply Agreement. 
 2.3. Manufacturing Practices. 

2.3.1. Specifications. Gen-Probe shall manufacture the Panther Instruments under this Supply Agreement in accordance with all Applicable
Laws and in accordance with the Specifications. Roka acknowledges that Gen-Probe may need to refine and modify the Specifications as Gen-Probe gains experience with the Manufacture, testing and use of the Panther Instruments. Accordingly, Gen-Probe
shall have the right to modify the Specifications and shall give Roka at least 30 days prior written notice of, and supply Roka with updated documentation in accordance with Gen-Probe’s Quality System with respect to, any such modifications to
the Specifications. 
 2.3.2. Quality. Gen-Probe shall provide Roka with such reasonable information, including manufacturing,
validation, quality systems and analytical documentation, and a certificate of conformance, as requested by Roka regarding quality control of the Manufacture of the Panther Instruments. The Parties intend to enter into a Quality Agreement, defining
the roles and responsibilities of Gen-Probe and Roka with respect to quality system interactions relating to the Panther Instrument. 
 2.4.
Assay Integration. Roka shall be responsible for the integration and testing of NATs developed by Roka for Industrial Applications on the Panther Instrument and the necessary testing to ensure that the assay sequence file developed by Roka
for each new assay (each, a “Roka Sequence File”) and related assay formulation functions properly with the Panther Instrument. To facilitate Roka’s integration of NATs, Gen-Probe shall provide Roka with: (a) Panther
Instrument-related documentation listed in Exhibit B hereto, and know-how reasonably needed by Roka to facilitate Roka’s responsibility to integrate its NATs for use on the Panther Instrument; (b) Panther Instrument-related
documentation and know-how reasonably needed by Roka to install software authorized by Gen-Probe on Panther Instruments; (c) Panther Instrument-related documentation and know-how reasonably needed by Roka

  
 -6- 

 
to upgrade Panther Instruments already in use by Roka’s customers to enable the use of any Roka NATs introduced after a Panther Instrument is in use in the field; and (d) electronic
documentation reasonably needed by Roka to develop training materials for operator training for the use of Panther Instruments in Industrial Applications. 

2.4.1. Assay Integration Services. Gen-Probe shall provide Roka with reasonable cooperation and coordination to assist Roka with its
responsibility to integrate Roka’s NATs on the Panther Instrument, including but not limited to (a) modifying the Panther Instrument software to permit the use of Roka’s NATs on the Panther Instrument, (b) providing Roka with an
APTIMA assay sequence file, (c) providing Roka with Exponential Tail Fit module with interface documentation, (d) reserving Gen-Probe unique assay type code numbers for Roka assays, (e) creating assay and system software disks (or
other electronic media) for Roka based on the Roka Sequence File provided to Gen-Probe by Roka, (f) performing testing procedures on the assay disk to confirm that the Roka Sequence File works with the Panther Instrument system software (such
testing procedures to be generally consistent with the testing procedures Gen-Probe performs on assay disks it prepares to support internally developed Gen- Probe assays) before returning the assay and system
software disks (or other electronic media) to Roka for assay verification and validation by Roka, and (g) providing all label and bottle specifications required to work with the APTIMA assay sequence file (collectively, “Assay Integration
Services”). Gen-Probe shall have no obligation under this Supply Agreement to the extent that Gen-Probe cannot provide Assay Integration Services due to Roka failing to timely deliver to Gen-Probe any data or information or failing to timely
take any action reasonably requested by Gen-Probe. Gen-Probe will use the same degree of care in rendering Assay Integration Services under this Supply Agreement as it utilizes in rendering such services for its own operations. 

2.4.2. Costs and Payments. For any Assay Integration Services provided to Roka by Gen-Probe, Roka shall pay to Gen-Probe: (a) a
fee equal to the sum of the fully burdened salary costs incurred by Gen-Probe for personnel in connection with the performance of such services, plus twenty percent (20%), and (b) all out-of-pocket expenses (including Third Party charges, if
any) incurred by Gen-Probe in providing such services ((a) and (b), collectively, “Services Costs”). Gen-Probe will invoice Roka on or about the tenth day of each calendar month for the amounts due under this Supply Agreement with respect
to the Assay Integration Services rendered in the prior month, which will consist of the Services Costs for such period. Such invoice will include reasonable detail regarding the components of the Services Costs and the calculation thereof. The
amounts specified in the invoice will be due within ten (10) Business Days after the delivery of the invoice to Roka. In the event Roka desires to dispute in good faith any item(s) under any invoice, Roka will provide Gen-Probe within five
(5) Business Days after delivery of the invoice with written notice setting forth the details of the disputed item(s) and the amount in question. Roka will timely pay to Gen-Probe all undisputed amounts on any such invoice. The Parties will
work together, in good faith, to resolve such dispute within five (5) Business Days after such notice of dispute is sent. If the Parties are unable to resolve a dispute within such five (5) Business Day period, the Parties shall escalate
such dispute for resolution pursuant to the provisions of Section 13.2 hereof. If escalation occurs, then Gen-Probe shall have the option to stop work under this Supply Agreement with respect to the
service(s) that are the subject of such dispute until the dispute is resolved unless Roka pays the disputed amount at the time the dispute is escalated for resolution. Roka’s failure to pay the portion(s) of an invoice that it disputes using
the procedure specified in this Section 2.4.3 shall not constitute a material breach under this Supply Agreement. 

  
 -7- 

 2.4.3. Panther Technical/Engineering Support. Gen-Probe shall use Commercially Reasonable
Efforts to provide Roka with access to Gen-Probe technical staff to troubleshoot difficult field issues that cannot be solved by reagent or hardware substitution and require advanced knowledge of the Panther Instrument, including without limitation
diagnosis and resolution of software anomalies and problems; provided, however, that Roka may not refer any such issues to Gen-Probe under this Section 2.4.3 without first using diligent efforts to resolve the issue by itself. Roka shall
reimburse Gen-Probe for such technical support on a fully burdened cost plus twenty percent (20%) basis (including time and materials). 

2.4.4. Impracticability; Additional Resources. Gen-Probe shall not be required to provide any Assay Integration Service (or other
service under this Section 2.4) to the extent the performance of such service becomes “impracticable” as a result of a cause or causes outside the reasonable control of Gen-Probe, or to the extent the performance of such service would
require Gen-Probe to violate any Applicable Laws, or would result in the breach of any software license or other applicable contract. Notwithstanding anything in this Section 2.4 to the contrary, if an event occurs that materially affects
Gen-Probe’s ability to provide any of the Assay Integration Services or other services or support pursuant to this Supply Agreement, Gen-Probe shall provide prompt written notice thereof to Roka, and the Parties shall then negotiate a
resolution in good faith. In providing the Assay Integration Services (or other services under this Section 2.4), Gen-Probe shall not be obligated to: (a) hire any additional employees; (b) maintain the employment of any specific
employee; (c) purchase, lease or license any additional equipment or software; or (d) pay any costs related to the transfer or conversion of Roka’s data to Roka or any alternate supplier of Assay Integration Services. 

 

	3.	FORECASTS; PURCHASE ORDERS; DELIVERY 

 3.1. Forecast of Requirements. 

3.1.1. Initial Forecast. Each Forecast under this Section 3.1 shall include the anticipated number of Panther Instruments and the
requested delivery dates. Roka previously provided Gen-Probe with a written Forecast covering its requirements for Panther Instruments for each of the four (4) Calendar Quarters in 2011 (the “2011 Forecast”). The 2011 Forecast shall
be binding on Roka. Gen-Probe responded to the 2011 Forecast in writing (which term expressly includes email correspondence) indicating whether and to what extent it will be able to commit to supply Roka with its requirements as indicated in the
2011 Forecast. Gen-Probe shall use Commercially Reasonable Efforts to meet the forecasted demand of Roka for Panther Instruments as to which Gen-Probe has undertaken an obligation to manufacture in accordance with the preceding sentence. 

3.1.2. Rolling Quarterly Forecasts. Beginning with the Calendar Quarter ending June 30, 2011, and on or prior to the last day of
the second to last month in each such Calendar Quarter, Roka shall update its prior Forecast by extending the Forecast to cover a period of not less than twelve (12) months starting with the first day of the second Calendar Quarter thereafter
(which date is 

  
 -8- 

 
referred to as the “Forecast Start Date”). As an example, the updated Forecast for the 12 month period from October 1, 2011 to September 30, 2012 will be provided by Roka to
Gen-Probe on or before May 31, 2011 and the “Forecast Start Date” for such Forecast shall be October 1, 2011. Gen-Probe shall respond to each Forecast in writing (which term expressly includes email correspondence) within thirty
(30) days indicating whether and to what extent it will be able to commit to supply Roka with its requirements as indicated in the applicable Forecast; provided, however, that for each Calendar Year after the 2011 Calendar Year Gen- Probe shall commit to supply Roka with an aggregate of at least 50 Panther Instruments per Calendar Year (so long as Roka’s Forecast for such Calendar Year is at least equal to an aggregate of 50 Panther
Instruments). For the avoidance of doubt, Gen-Probe shall not decline to commit to supply Roka with any portion of Roka’s Forecasted requirements to the extent that Gen-Probe and/or its Third Party contract manufacturer has the production
capacity to first meet all of Gen-Probe’s requirements for itself and for Gen-Probe’s other customers, and to fill such Roka Forecasted requirements or portions thereof. Notwithstanding the foregoing, the Parties acknowledge and agree that
with respect to requirements for Panther Instruments in 2011 such updated Forecasts shall be for planning purposes only because the final version of the 2011 Forecast shall control with respect to Roka’s requirements for Panther Instruments in
2011. Absent Gen-Probe’s prior written consent, with respect to each such updated Forecast, Roka may not modify the previously-forecasted amount of Panther Instruments for the Calendar Quarter following the Forecast Start Date, and Roka may not
increase or decrease its Forecast for Panther Instruments for the Calendar Quarter covering the fourth through sixth months of the Forecast by more than twenty-five percent (25%) from the previously forecasted amount for such Calendar Quarter.

 3.1.3. Forecast Factors. Roka shall prepare each Forecast based upon Roka’s good faith determination of the past and
reasonably anticipated market demand for Panther Instruments thereof. In arriving at Forecasts, Roka shall consider standard production planning parameters, including but not limited to sales forecasts, sales demand forecasts, inventory
requirements, and the like. In addition, Roka’s Forecasts for Panther Instruments in 2011 shall in good faith recognize limitations imposed by Gen-Probe’s arrangements with its Third Party contract manufacturer for the manufacture and
supply of such Panther Instruments. 
 3.1.4. Initial Supply Period. Notwithstanding the foregoing, the parties recognize that
forecasting and manufacturing for and during the first twelve months of supply hereunder (the “Initial Supply Period”) will be difficult and that actual experience may vary significantly from any Forecast, and the parties agree to work
together to address the manufacture and supply of Panther Instruments, and to use Commercially Reasonable Efforts to satisfy the market demand for such Panther Instruments, during the Initial Supply Period. Furthermore, Roka acknowledges and agrees
that the Panther Instruments are in the early stages of commercialization and that as a result Gen-Probe may not be able to deliver the Panther Instruments to Roka on a timely basis during the Initial Supply Period. Without limiting the generality
of the foregoing, Roka acknowledges that delivery of the Panther Instruments to Roka is subject to Gen-Probe’s timely receipt of the Panther Instruments from its Third Party contract manufacturer, the availability of sufficient Panther
Instruments to accommodate Gen-Probe’s other customers, as determined by Gen-Probe in its reasonable discretion, and other potential delays. 

  
 -9- 

 3.2. Purchase Obligation. Together with delivery of the 2011 Forecast pursuant to
Section 3.1.1 above, Roka shall deliver to Gen-Probe a binding Purchase Order for its requirements of Panther Instruments as reflected in the 2011 Forecast, which shall specify the quantity ordered and the requested delivery date(s). On or
before October 1, 2011, Roka shall deliver to Gen-Probe a binding Purchase Order for its requirements of Panther Instruments for delivery during the first Calendar Quarter of 2012, which shall specify the quantity ordered and the requested
delivery date(s) and which shall be consistent with the Forecast for such Calendar Quarter (as finally determined in accordance with the procedures specified in Section 3.1 above). Thereafter, on or before the first day of the first Calendar
Quarter of 2012 and each succeeding Calendar Quarter, Roka shall deliver to Gen-Probe a binding Purchase Order for its requirements of Panther Instruments for delivery during the following Calendar Quarter, which shall specify the quantity ordered
and the requested delivery date(s) and which shall be consistent with the Forecast for such Calendar Quarter (as finally determined in accordance with the procedures specified in Section 3.1 above). Gen-Probe shall confirm all Purchase Orders
within the Forecasted amounts, including quantities and delivery dates, in writing within ten (10) Business Days after receipt of Purchase Orders. 

3.3. Orders. Notwithstanding the content of a Purchase Order, Gen-Probe’s invoice, or any other document submitted by one party to
the other, this Supply Agreement shall take precedence over such Purchase Order or other document, and this Supply Agreement shall govern and control over any conflicting or inconsistent terms of such Purchase Order(s), invoice(s) or other
documents, and all terms which are inconsistent with those provided in this Supply Agreement shall be null and void. 
 3.4. Supply
Obligation. Gen-Probe shall be required to supply in any Calendar Quarter the quantity of such Panther Instruments ordered by Roka pursuant to Section 3.2 to the extent such quantity of Panther Instruments was set forth in the most recent
Forecast. If the quantity of Panther Instruments ordered by Roka under Section 3.2 for any Calendar Quarter exceeds the forecasted amount, Gen-Probe shall use Commercially Reasonable Efforts to work with its Third Party contract manufacturer to
supply such excess. If Gen-Probe becomes aware of any fact indicating that Gen-Probe may be unable to meet Roka’s forecasted demand for Panther Instruments, Gen-Probe shall promptly provide written notice of such fact to Roka. 

3.5. Delivery Dates. Gen-Probe shall use Commercially Reasonable Efforts to ship the Panther Instruments on the date requested in any
accepted Purchase Order, provided that such date is consistent with the terms and conditions of this Supply Agreement. Gen-Probe shall promptly notify Roka of any delay and shall keep Roka informed throughout the duration of the delay. In the event
of any delay in the scheduled delivery date, and without limiting Roka’s other rights and remedies hereunder, Gen-Probe shall immediately notify Roka of such delay and shall work diligently to remedy such delay. 

 

	4.	ALLIANCE MANAGERS 

 4.1. Alliance Management Structure. The Parties have each
previously designated a single representative to serve as the primary point-of-contact for matters relating to the interactions between the Parties (each such person, an “Alliance Manager”). As of the date of this Supply Agreement, the
Gen-Probe Alliance Manager is [*] and the Roka Alliance Manager is [*]. Each of Gen-Probe and Roka 

  
 -10- 

 
shall have the right to designate a substitute or replacement Alliance Manager from time to time in its sole discretion, effective upon notice to the other Party of such change. In addition, each
Party shall have the right to have a reasonable number of ad-hoc additional representatives of such Party attend meetings of the Alliance Managers from time to time. 

4.2. Meetings. The Alliance Managers shall meet in person or by teleconference on a quarterly basis, or at such other frequency as
mutually determined by the Alliance Managers, to discuss issues related to Manufacture of the Panther Instruments. As part of their duties, the Alliance Managers shall review and discuss the status of Forecasts, orders, delivery schedules, assay
integration issues, and any other issues related to Gen-Probe’s supply of Panther Instruments to Roka, and such other subjects as mutually determined by the Alliance Managers. The Parties shall agree in advance upon the time and place of such
meetings. 
  

	5.	PRODUCT DELIVERY AND ACCEPTANCE 

 5.1. Delivery. All Panther Instruments supplied
to Roka under this Supply Agreement shall be EXW (Incoterms 2000) Gen-Probe’s Third Party cross-dock facility (the “Cross-Dock Facility”) located at Agility Logistics AG, Frachtgebäude Südzone, 4030 Basel Flughafen/Airport,
Switzerland or Gen-Probe’s distribution center (the “UK Distribution Center”) located in Manchester, England. Roka shall be responsible for all freight, insurance charges, taxes, import and export duties, inspection fees and other
charges applicable to the sale and transport of Panther Instruments purchased by Roka hereunder. Title and risk of loss and damage to the Panther Instruments purchased by Roka hereunder shall pass to Roka upon receipt by Roka’s designated
carrier at the Cross-Dock Facility or the UK Distribution Center, as applicable. Gen-Probe shall use Commercially Reasonable Efforts to arrange warehouse capacity for Panther Instruments at the UK Distribution Center after sale to Roka and pending
further delivery instructions from Roka. Roka will be solely responsible for the cost of any such warehouse capacity utilized by Roka. 

5.2. Inspection of Delivered Product. If any Panther Instrument is damaged, defective or fails to conform to the Specifications during
the Warranty Period (as defined in Section 5.3 below), then Roka shall have the right to reject such damaged, defective or non-conforming Panther Instrument. Roka shall give written notice to both
Gen-Probe and any manufacturer designated by Gen-Probe of its rejection hereunder, within thirty (30) days after installation of such Panther Instrument, specifying the grounds for such rejection. The Panther Instrument shall be held for
Gen-Probe’s disposition, at Gen-Probe’s expense, if found to be damaged, defective or non-conforming. Gen-Probe shall use Commercially Reasonable Efforts to repair or replace such rejected Panther Instruments after receipt of notice of
rejection thereof. If the Parties dispute whether a Panther Instrument rejected by Roka conforms to the Specifications, the Parties shall resolve the issue pursuant to Section 13.2. The acceptance by Roka of Panther Instruments under this
Section 5.2 shall not be deemed a waiver or limitation in any manner or respect of the representations and warranties made by Gen-Probe hereunder. 

5.3. Warranty. Gen-Probe represents and warrants to Roka that the Panther Instruments supplied to Roka hereunder will conform to the
Specifications (as may be modified from time to time in accordance with this Supply Agreement), will be in compliance with all 

  
 -11- 

 
Applicable Laws in the EU and USA and will be free from defects in material, workmanship and design. Each Panther Instrument shall be warranted for eighteen (18) months from the date of shipment
from Gen-Probe’s Third Party contract manufacturer or for twelve (12) months following installation at Roka’s customer location, whichever occurs first (such period, the “Warranty Period”). Any and all warranties by any contract
manufacturer of a Panther Instrument shall inure to the benefit of Roka to the extent permitted by such contract manufacturer. Any unauthorized modification of the Panther Instrument by Roka (or Roka’s customer) shall void the foregoing
warranty. For the avoidance of doubt, Roka’s installation of software approved in advance by Gen-Probe on a Panther Instrument shall not constitute an unauthorized modification that voids the foregoing warranty. For the further avoidance of
doubt, the Parties agree that Gen-Probe’s warranty obligations hereunder shall only include instrument failures resulting from instrument design and/or manufacturing, and that Gen-Probe’s warranty obligations shall not include instrument
failures resulting from user error or poor field service, instrument failures caused by the Roka Sequence File or assay formulation, or other causes beyond the reasonable control of Gen-Probe or its Third Party contract manufacturer. Without
limiting the generality of the foregoing, the warranty set forth in this Section 5.3 will not apply in the event that: (a) Roka (or Roka’s customer) has not used and maintained the Panther Instrument in accordance with the
Specifications and/or the operator’s manual provided by Gen- Probe to Roka; (b) Roka (or Roka’s customer) has used the Panther Instrument with reagents and supplies not expressly authorized by
Gen-Probe, it being agreed that the reagents and supplies listed on Schedule 5.3 attached hereto that Roka procures from Gen-Probe shall be deemed authorized by Gen-Probe, provided that such reagents and supplies are used by Roka in
accordance with the applicable specifications; (c) the Panther Instrument is repaired, modified or altered by a party other than Gen-Probe or Roka without Gen-Probe’s prior written consent; (d) Roka (or Roka’s customer) has
installed software on the Panther Instrument that was not authorized in advance by Gen-Probe; (e) the Panther Instrument has been subject to misuse, negligence or other accident; or (f) the use of the Panther Instrument did not comply with
the requirements specified on Exhibit E attached hereto and incorporated herein by reference. 
 Since the Panther Instrument was
designed for use in Clinical Diagnostics and not for use in the Roka Field, Gen-Probe intends to keep track of warranty claims made on the Panther Instruments used in the Roka Field (the “Roka Warranty Claims”) as compared to warranty
claims made on the Panther Instruments used for Clinical Diagnostics (the “Non-Roka Warranty Claims”). In general, the parties anticipate that the rate and average cost of Roka Warranty Claims will be similar to the rate and average cost
of Non-Roka Warranty Claims. To the extent that the rate and/or average cost of Roka Warranty Claims is disproportionate to the rate and/or average cost of Non-Roka Warranty Claims measured over a period of at least twelve (12) consecutive
months, Gen-Probe will share such information with Roka and the parties will (i) review and evaluate the Roka Warranty Claims, (ii) consider ways to address the lack of proportionality between the rate and/or average cost of Roka Warranty
Claims and the rate and/or average cost of Non-Roka Warranty Claims and (iii) use good faith efforts to enter into an amendment to this Supply Agreement to modify the terms of Section 5.3 on a prospective basis. 

5.4. No Additional Warranties. EXCEPT AS EXPRESSLY PROVIDED IN SECTION 5.3 ABOVE, GEN-PROBE MAKES NO WARRANTIES (EXPRESS, IMPLIED,
STATUTORY OR OTHERWISE) WITH RESPECT TO THE SUBJECT MATTER HEREOF, AND GEN-PROBE SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF :MERCHANTIBILITY AND/OR FTINESS FOR A PARTICULAR PURPOSE. 

  
 -12- 

 5.5. Remedies for Non-Conforming Product. In the event that a Panther Instrument fails to
conform to the warranty set forth in Section 5.3 above and Gen-Probe receives written notice from Roka of such non-conformity within the Warranty Period, Gen-Probe shall: 

5.5.1.Promptly investigate such non-conformity, and deliver to Roka a corrective action plan within thirty (30) days after receipt of
Roka’s written notice of non-conformity, or such additional time as is approved by Roka if such investigation or plan requires data from sources other than Roka or Gen-Probe. 

5.5.2. At Gen-Probe’s expense, repair or replace such non-conforming Part(s) as soon as reasonably practicable with Part(s) that conform
to the Specifications and refund any freight charges (and related taxes and duties) incurred by Roka related to such non-conforming Part(s). The labor for the replacement of such Part(s) shall be provided by Roka. 

5.5.3. In the event Roka is unable to repair or replace such non-conforming Part(s), Gen-Probe at its discretion shall either repair or
replace such non-conforming Panther Instrument(s) as soon as reasonably practicable with Panther Instrument(s) that conform to the Specifications and refund any freight charges (and related taxes and duties) incurred by Roka related to such
non-conforming Panther Instrument(s). 
 5.6. LIMITATION OF LIABILITY. EXCEPT AS OTHERWISE SPECIFICALLY SET FORTH IN THIS SUPPLY
AGREEMENT, GEN-PROBE’S SOLE LIABILITY TO ROKA, AND ROKA’S SOLE REMEDY, WITH RESPECT TO THE SPECIFIC MATTERS ADDRESSED UNDER SECTIONS 5.2, 5.3 AND 5.5 HEREOF SHALL BE THE REJECTION AND REPLACEMENT OF
NON-CONFORMING PANTHER INSTRUMENTS (OR PARTS THEREOF). NOTHING IN THIS SECTION SHALL LIMIT ANY RIGHTS OR REMEDIES UNDER ARTICLE 11 OR ANY RIGHT OF ROKA TO ASSUME RESPONSIBILITY FOR THE MANUFACTURE OF THE
PANTHER INSTRUMENTS UNDER ARTICLE 8. 
 5.7. Failure to Supply. If Gen-Probe fails to supply all or any material part of a quantity
of Panther Instruments specified by Roka in a Purchase Order accepted by Gen-Probe, Roka may elect, at its sole discretion, to require Gen-Probe to supply the undelivered Panther Instruments or a lesser quantity at a future date agreed upon by
Gen-Probe and Roka. The provisions of this Section 5.7 shall be without prejudice to Roka’s rights under Article 9 (Term and Termination) of this Supply Agreement and remedies provided for hereunder or any other rights or remedies
available to Roka including, without limitation, those under this Supply Agreement. 
 5.8. Updates and Improvements. Gen-Probe shall
make available to Roka, on a fully burdened cost plus 20% basis, for retrofitting or upgrading any Panther Instruments previously purchased by Roka from Gen-Probe, any modified or upgraded software, component or other improvement to the Panther
Instruments developed during the Term which Gen-Probe has made generally available to the then outstanding Panther Instruments deployed in the field by Gen-Probe for Clinical Diagnostics; provided, however, that software upgrades that are released
to correct errors or fix other software bugs shall be provided at no cost to Roka (except with respect 

  
 -13- 

 
to the installation thereof as described below). Notwithstanding the foregoing, (i) Roka shall be responsible for installing all such software updates (including labor costs associated with
the installation of such software updates) on all Panther Instruments previously purchased by Roka hereunder and (ii) Roka shall be solely responsible for all costs associated with modifications or upgrades specifically requested by Roka or for
features designed specifically for use in the Roka Field (it being understood that Gen-Probe shall have the absolute right to decline any such requests for modifications, upgrades or features from Roka). Gen-Probe shall make available to Roka on
reasonable terms mutually agreed upon technical assistance as may be needed to implement any such improvements in Panther Instruments previously purchased by Roka on a fully burdened cost plus 20% basis. 

5.9. Spare Parts. The parties shall enter into an agreement setting forth their rights and obligations with respect to spare parts and
support to enable remote diagnostics, which, when executed, shall be incorporated into and be deemed Exhibit C to this Supply Agreement. The parties recognize that such an agreement will not be completed before the execution of this Supply
Agreement. Prior to the completion and execution of the contemplated spare parts agreement, Gen-Probe shall use Commercially Reasonable Efforts to make spare parts for Panther Instruments purchased by Roka hereunder available for purchase by Roka on
a fully burdened cost plus 20% basis. 
 5.10. Training. Gen-Probe shall make training services available to Roka with respect to the
Panther Instrument in accordance with the schedule attached hereto as Exhibit D. 
 5.11. Independent Purchaser Status. Roka
shall be an independent purchaser and reseller of Panther Instruments. Roka shall be free to use and resell the Panther Instrument in the Roka Field on such terms as it may, in its sole discretion, determine, including price, returns, credits and
discounts. 
 5.12. Invoices. Upon shipment of Panther Instruments to Roka, Gen-Probe shall submit invoices therefore to Roka. 

5.13. Sales and Use Tax. Any foreign, federal, state, county or municipal sales or use tax (including VAT), excise or similar charge,
or other tax assessment (other than that assessed against income), assessed or charged on the sale of Panther Instruments sold by Gen-Probe to Roka pursuant to this Supply Agreement shall be paid by Roka. 

5.14. Withholding Taxes. Roka shall be entitled to deduct the amount of any withholding taxes, value-added taxes or other taxes, levies
or charges (other than United States taxes) with respect to amounts payable on Panther Instruments to the extent Roka or its distributors pay to the appropriate governmental authority on behalf of Gen-Probe such taxes, levies or charges. Roka shall
use reasonable efforts to minimize any such taxes, levies or charges required to. be withheld on behalf of Gen-Probe by Roka or its distributors. Roka promptly shall deliver to Gen-Probe proof of payment of all such taxes, levies and other charges,
together with copies of all communications from or with such governmental authority with respect thereto. 

  
 -14- 

 5.15. Non-Commercial Panther Instruments. Roka acknowledges that Gen-Probe has previously
provided Roka with five (5) Internal - Use Instruments (as defined below). Gen-Probe agrees to provide to Roka not more than fourteen (14) additional Panther Instruments (for a total of nineteen (19) Internal Use Instruments) for
internal uses, including without limitation research studies, marketing studies, internal research and development, and troubleshooting (all for Roka’s use only in direct furtherance of the express purposes of this Supply Agreement and without
any implied license for any purpose other than such express purposes), to the extent such Panther Instruments are specifically ordered for such purposes (“Internal Use Instruments”). The entire compensation to Gen-Probe for Internal Use
Instruments shall be one hundred twenty percent (120%) of Gen-Probe’s Manufacturing Cost for such Panther Instruments, provided that if the Internal Use Instruments sold hereunder are used by Roka other than solely for Roka’s internal
purposes as permitted hereby, the amount due hereunder for each such Internal Use Instrument shall be increased to an amount equal to the price specified in Section 6.2 hereof. Notwithstanding anything to the contrary set forth elsewhere
herein, the entire compensation for all such Internal Use Instruments shall be due and payable upon delivery of such Internal Use Instruments to Roka. In addition, Roka acknowledges and agrees that the delivery of any such Internal Use Instruments
may be subject to delays in order to allow for the delivery of Panther Instruments to other Gen-Probe customers. 
 5.16. Marketing;
Customer Service; Branding. During the Term, Roka shall use Commercially Reasonable Efforts to promote and sell the Panther Instrument and Panther- Related Products in the Territory and to provide customer
service consistent with industry standards. Roka shall market and sell the Panther Instruments under a brand name determined by Roka in its discretion that shall not include the term “Panther” or “Tigris,” subject to the
reasonable review and approval of Gen-Probe, such review and approval to be provided within thirty (30) days. During the first 24 months of the initial Term of this Supply Agreement, Roka shall provide to Gen-Probe for Gen-Probe’s prior
review and approval copies of all promotional materials which Roka proposes to use with respect to the Panther Instrument and Panther- Related Products. Such materials shall be deemed approved unless Gen-Probe
objects to such materials within thirty (30) days of receipt of such materials from Roka. Roka acknowledges that there will be a delay of up to 120 days from the time that final Roka-branded artwork is provided to Gen-Probe before such
Roka-branding will be included in Panther Instruments ordered by Roka hereunder. 
 5.16.1.Gen-Probe shall be responsible for modifying the
Panther Instrument software to (a) replace the “Panther”-branded splash screen with a Roka-branded splash screen and (b) replace all “Panther” branding with Roka branding on all appropriate Panther Instrument software
screens, help guides (including the online user manual included as part of the Panther Instrument) and reports, provided that the revised Roka branding is the same size as the Gen- Probe branding which is
being replaced. Gen-Probe shall perform limited testing procedures to confirm that such modifications do not have an adverse effect on the performance of the Panther Instrument software. 

5.16.2. Subject to the last sentence of Section 5.16, Gen-Probe shall place the “Roka Bioscience” brand on agreed locations on
Panther Instruments delivered to Roka, using artwork supplied by Roka. 

  
 -15- 

 5.16.3. For any services provided to Roka by Gen-Probe under Section 5.16.1 and
Section 5.16.2 above, Roka shall pay to Gen-Probe: (a) a fee equal to the sum of the fully burdened salary costs incurred by Gen-Probe for personnel in connection with the performance of such services, plus twenty percent (20%), and
(b) all out-of-pocket expenses (including Third Party charges, if any) incurred by Gen-Probe in providing such services. 
  

	6.	PAYMENT 

 6.1. Currency. All invoices issued and payments made pursuant to this
Supply Agreement shall be in United States Dollars. To the extent that Gen-Probe’s Manufacturing Costs are incurred in any currency other than United States Dollars, Gen-Probe shall determine the Dollar amounts in invoices based on the
conversion of Manufacturing Costs denominated in foreign currency from the applicable currency units to Dollars on the date that the invoice was issued to Gen-Probe by its Third Party contract manufacturer, using the currency rates section of The
Financial Times published on such date. 
 6.2. Invoice and Payment for Product. For each Panther Instrument, Roka shall pay
Gen-Probe the price set forth in Section 2.2 hereof, payable as set forth in this Article 6. Gen- Probe shall provide Roka with an invoice for the total price for each Panther Instrument concurrently with
each delivery of such Panther Instrument. Each invoice shall, to the extent applicable, identify Roka’s Purchase Order number, Panther Instrument numbers, names and quantities, unit price and the total amount to be remitted by Roka. Of the
total amount reflected on the invoice for the Panther Instrument(s), one-half shall be paid by Roka no later than forty- five (45) days after receipt of the invoice or delivery of the Panther Instruments
covered by the invoice to the Cross-Dock Facility or the UK Distribution Center, as the case may be, whichever occurs last, and the remaining one-half shall be paid in accordance with Section 6.3. Notwithstanding the foregoing, the payment
terms for the first 75 Panther Instruments ordered by Roka hereunder (excluding Internal Use Instruments purchased by Roka under Section 5.15 above) shall be modified as follows: two-thirds of the total amount reflected on the invoice for the
Panther Instrument(s) shall be paid by Roka no later than forty-five (45) days after receipt of the invoice or delivery of the Panther Instruments covered by the invoice to the Cross-Dock Facility or the UK Distribution Center, as the case may
be, whichever occurs last, and the remaining one-third shall be paid in accordance with Section 6.3. For the avoidance of doubt, Roka shall be entitled to appropriate reimbursement from Gen-Probe should any audit under Section 7.2 reveal
that the actual Manufacturing Costs for a particular year were lower than the amount charged by Gen-Probe to Roka therefor. 
 6.3.
Margin Recovery. With respect to each Panther Instrument, Roka shall pay one-half of the Panther Instrument price (or, in the case of the first 75 Panther Instruments ordered by Roka hereunder (excluding Internal Use Instruments purchased by
Roka under Section 5.15 above), one-third of the Panther Instrument price) (such amount, the “Margin Recovery Amount”) over time in increments computed as 1.00% of Roka’s Net Sales, until such time as the Margin Recovery Amount
has been paid in full to Gen-Probe with respect to such Panther Instrument, in accordance with the provisions of this Section 6.3; provided, however, that if the Margin Recovery Amount with respect to a Panther Instrument has not
been fully paid by the end of the fifty-fourth (54th) month after delivery of such Panther Instrument to Roka, then any such remaining portion of the Margin Recovery Amount for a Panther
Instrument shall be immediately due and payable by Roka to Gen-Probe. 

  
 -16- 

 6.4. Margin Recovery Payments. All Margin Recovery Amount payments due to Gen-Probe under
Section 6.3 shall be paid within 60 days of the end of each Calendar Quarter. Each such payment shall be accompanied by a report of Net Sales of Panther Instruments and Panther-Related Products by Roka and its Affiliates, licensees and
sublicensees for the Calendar Quarter in sufficient detail to permit confirmation of the accuracy of the payment made for such Calendar Quarter, including, on a country-by-country basis, the quantity of Panther Instruments and Panther-Related
Products sold, the gross sales and Net Sales of such Panther Instruments and Panther-Related Products, and the exchange rates used. If at any time legal restrictions prevent the prompt remittance of part or all of the Margin Recovery Amount with
respect to any country in the Territory where Panther Instruments are sold, payment shall be made through such lawful means or methods as the parties reasonably shall determine. For purposes of allocating the total Margin Recovery Amount for each
Calendar Quarter to each Panther Instrument, Roka shall divide the total Margin Recovery Amount paid for the Calendar Quarter by the number of Panther Instruments for which a Margin Recovery Amount is still due and owing, to determine an average
per-Panther Instrument Margin Recovery Amount for that Calendar Quarter. The average per-Panther Instrument Margin Recovery Amount for that Calendar Quarter shall then be applied to the remaining balance due for each Panther Instrument as to which a
Margin Recovery Amount remains due and owing. 
  

	7.	RECORDS. INSPECTIONS AND AUDITS 

 7.1. Records. The Parties shall during the Term
(including any renewal thereof) maintain complete and accurate books and records with respect to any and all transactions relating and pertaining to this Supply Agreement. 

7.2. Manufacturing Cost Audit. Upon sixty (60) days’ prior written notice, Gen-Probe shall permit its books and records of
Manufacturing Costs to be examined for a particular calendar year, no more than once annually, during normal business hours, by an independent auditor appointed by Roka and reasonably acceptable to Gen-Probe, and at Roka’s expense, to the
extent necessary to verify all Manufacturing Costs and the invoices delivered by Gen-Probe under this Supply Agreement. Any such audit will be conducted in such a manner to minimize disruptions to Gen-Probe’s business and operations. Any
information received during or as a result of such inspection shall be maintained as Gen-Probe’s Confidential Information in accordance with the terms of the Confidentiality Agreement. Roka may only use this information, and disclose it to its
employees and advisers, as necessary for Roka to exercise its rights under this Supply Agreement. Roka shall not disclose this information to any Third Party other than accounting and consulting professionals assisting Roka in the audit who agree to
maintain the confidentiality of the information in accordance with the terms of the Confidentiality Agreement. 
 7.3. Manufacturing
Quality Audit. Roka shall have the right, at its sole expense, to audit Gen-Probe for compliance with Section 2.3 upon reasonable prior notice to Gen-Probe during normal business hours and not more than once in each calendar year (or such
additional times as may be necessary to ensure compliance with all material requirements). Any such audit will be conducted 

  
 -17- 

 
in such a manner to minimize disruptions to Gen-Probe’s business and operations. Any information received during or as a result of such audit shall be maintained as Gen-Probe’s
Confidential Information in accordance with the terms of the Confidentiality Agreement. Roka may only use this information, and disclose it to its employees and advisers, as necessary for Roka to exercise its rights under this Supply Agreement. Roka
shall not disclose this information to any Third Party other than technical consultants assisting Roka with such audit who agree to maintain the confidentiality of such information in accordance with the terms of the Confidentiality Agreement. 

7.4. Assay Integration Services Audit. Roka shall have the right, at its sole expense, to audit and examine any cost, payment, or
supporting documentation resulting from the provision of any of the Assay Integration Services upon reasonable prior notice to Gen-Probe during normal business hours and not more than once in each calendar year. Any such audit(s) shall be undertaken
by Roka, or its representative from a certified public accounting firm, in conformance with generally accepted auditing standards then applicable. Gen-Probe agrees to fully cooperate with any such audit(s). Any such audit will be conducted in such a
manner to minimize disruptions to Gen-Probe’s business and operations. Any information received during or as a result of such audit shall be maintained as Gen-Probe’s Confidential Information in accordance with the terms of the
Confidentiality Agreement. Roka may only use this information, and disclose it to its employees and advisers, as necessary for Roka to exercise its rights under this Supply Agreement. Roka shall not disclose this information to any Third Party other
than technical consultants assisting Roka with such audit who agree to maintain the confidentiality of such information in accordance with the terms of the Confidentiality Agreement. 

 

	8.	ALTERNATIVE SUPPLY 

 8.1. Alternative Supplier. Roka shall have the right to
contract with a Third Party (“Alternative Supplier”) reasonably acceptable to Gen-Probe to Manufacture and fill Roka’s requirements for Panther Instruments if (a) Gen-Probe provides notice of intent not to renew this Supply
Agreement pursuant to Section 9.1 hereof, (b) Roka terminates this Supply Agreement pursuant to Section 9.2 (but only with respect to a material breach by Gen-Probe of its obligations under Section 2.4, Section 5.5,
Section 5.9 or Section 5.10) or Section 9.3 or (c) during the Term of this Supply Agreement (i) Gen-Probe becomes bankrupt or insolvent or (ii) Gen-Probe ceases production of the Panther Instruments for any other reason
(each of the foregoing events described in clauses (a), (b) or (c) above referred to as an “Alternative Supplier Trigger”). The parties acknowledge and agree that Stratec Biomedical Systems AG (“Stratec”) qualifies as
an “Alternative Supplier” hereunder. In the event Roka’s rights to contract with an Alternative Supplier under this Article 8 are triggered, Gen-Probe will (i) allow Stratec to act as the Alternative Supplier to Roka hereunder
and (ii) waive any covenants or other applicable restrictions in connection therewith. In the event that an Alternative Supplier Trigger occurs and Roka elects to contract with an Alternative Supplier, Roka shall provide written notice of such
election to Gen-Probe (“Alternative Supplier Notice”). Roka acknowledges that it shall not have a right to purchase Panther Instruments from an Alternative Supplier under clause (a) above until expiration of the then current term of
the Supply Agreement, provided that Gen-Probe continues to fully perform its obligations under this Supply Agreement during the period following notice of non-renewal of this Supply Agreement (the “Non-Renewal Window”). For the avoidance
of doubt, Roka shall have the right during the Non-Renewal Window to take all steps necessary 

  
 -18- 

 
to prepare for and ensure that, through its Alternative Supplier, it will have an uninterrupted supply of Panther Instruments upon expiration of this Supply Agreement, including entering into a
supply agreement with the Alternative Supplier, and Gen-Probe shall cooperate with and assist Roka during the Non-Renewal Window in accordance with Section 8.2 below. 

8.2. Alternative Supplier License. In the event that Roka contracts with an Alternative Supplier with respect to Panther Instruments
pursuant to Section 8.1, the Parties agree that with respect to the Panther Instruments: 
 8.2.1. Roka shall retain all rights
conferred by this Supply Agreement reasonably necessary to facilitate Roka’s or its Affiliates’ continued Commercialization of the Panther Instruments without interruption for so long as Roka or an Affiliate markets and sells the Panther
Instruments; 
 8. 2. 2. Subject to an appropriate confidentiality agreement with such Alternative Supplier, Gen-Probe shall (i) grant
to the Alternative Supplier a non-exclusive, irrevocable license, without the right to grant sublicenses, in and to any Gen-Probe Know How or other Gen- Probe Intellectual Property Rights, (ii) deliver
information and documentation and (iii) use Commercially Reasonable Efforts to assign, sublicense and/or transfer to the Alternative Supplier any necessary Gen-Probe rights in Third Party Intellectual Property Rights (in accordance with the
terms of any such Third Party Intellectual Property Rights), that is, in each case, reasonably necessary for the Alternative Supplier to Manufacture and/or supply the Panther Instruments to Roka and to permit Roka without supply interruption to
continue to Commercialize the Panther Instruments in the Territory; and 
 8.2.3. Gen-Probe shall supply to the Alternative
Supplier commercially reasonable technology transfer and other assistance reasonably necessary for the Alternative Supplier to Manufacture and/or supply the Panther Instruments to Roka. Roka will be responsible for any reasonable technology transfer
fees associated with the technology transfer to such Alternative Supplier, which the Parties shall agree to in advance of the technology transfer, unless the Alternative Supplier Trigger occurs pursuant to Section 8.l(b) above, in which case
Gen-Probe shall be responsible for any such technology transfer costs. 
 8.2.4. The parties agree that Roka shall pay to Gen-Probe a
reasonable royalty or other amount mutually determined by Gen-Probe and Roka (or in accordance with Section 13.2 if the parties are unable to agree on such royalty or other amount) that is calculated to compensate Gen-Probe for the use of the
Gen-Probe Intellectual Property Rights in connection with the continued Manufacture of the Panther Instruments. 
 8.3. Material
Term. The Parties acknowledge and agree that Gen-Probe’s failure to perform any part of this Article 8 shall be a material breach of this Supply Agreement. The provisions of this Article 8 shall be without prejudice to Roka’s rights
under Article 9 (Term and Termination) of this Supply Agreement and any and all remedies provided for hereunder or thereunder or any other rights or remedies available to Roka. Gen-Probe acknowledges that an uninterrupted supply of Panther
Instruments is critical to Roka’s business, and agrees that, in the event of a breach by Gen-Probe of Article 8 of this Supply Agreement, Roka shall be entitled to seek specific performance of Gen-Probe’s obligations under this Article 8.

  
 -19- 

	9.	TERM AND TERMINATION 

 9.1. Term. The term of this Supply Agreement
(“Term”) shall commence on the Effective Date and shall continue thereafter for an initial period of seven (7) years, after which it shall renew automatically for successive two (2) year periods unless either party provides the
other party with written notice at least twelve (12) months in advance of a scheduled renewal date of its intent not to renew the Supply Agreement. 

9.2. Termination for Cause. Either Party may terminate this Supply Agreement for any breach of a material provision of this Supply
Agreement by the other Party sixty (60) Business Days after written notice containing details of the breach if the breach remains uncured at the end of the notice period. With respect to a default or breach of this Supply Agreement, failure of
a Party to provide notice to the defaulting or breaching Party as required by this Section 9.2 shall not constitute a waiver of the right to give such notice with respect to any subsequent default or breach. 

9.3. Supply Failure Termination. Roka shall have the right to terminate this Supply Agreement upon thirty (30) Business Days
written notice to Gen-Probe if, for any reason other than as a result of a breach by Roka under this Supply Agreement or an event of force majeure contemplated by Section 13.5 below, Gen-Probe fails to supply (a) at least fifty percent
(50%) of Roka’s Forecasted Requirements for the Panther Instruments in Calendar Year 2012 or Calendar Year 2013, (b) at least sixty-five percent (65%) of Roka’s Forecasted Requirements for the Panther Instruments in Calendar
Year 2014, (c) at least seventy-five percent (75%) of Roka’s Forecasted Requirements for the Panther Instruments in Calendar Year 2015 or any Calendar Year thereafter during the Term, or (d) Roka with at least 50 Panther
Instruments for any Calendar Year after the 2011 Calendar Year (so long as Roka’s Forecast for such Calendar Year is at least equal to an aggregate of 50 Panther Instruments); provided, however, that with respect to (a), (b), (c) or (d),
Roka’s orders in the applicable Calendar Year do not exceed the most recent Forecast for such Calendar Year by more than twenty-five percent (25%). 

9.4. Effects of Termination. 

9.4.1. In the event of termination of this Supply Agreement by Gen-Probe pursuant to Section 9.2, Roka shall promptly return to Gen-Probe
all materials and records in Roka’s and its Affiliates’ possession or control containing Confidential Information of Gen- Probe relating to the Panther Instrument. 

9.4.2. In the event of termination of this Supply Agreement by Roka pursuant to Sections 9.2 or 9.3, Gen-Probe shall promptly return to Roka
all materials and records in Gen- Probe’s and its Affiliates’ possession or control containing Confidential Information of Roka relating to the Panther Instrument. 

9.5. Bankruptcy. To the extent permitted under applicable law, either Party may terminate this Supply Agreement effective immediately
with written notice if the other Party shall file for bankruptcy, shall be adjudicated bankrupt, shall file a petition under insolvency laws, shall be dissolved or shall have a receiver appointed for substantially all of its property. 

  
 -20- 

 All rights and licenses granted under or pursuant to any Section of this Supply Agreement are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property’’ as defined under Section 101(35A) of the Bankruptcy Code. The Parties shall retain and may
fully exercise all of their respective rights and elections under the Bankruptcy Code. Upon the bankruptcy of Gen-Probe, Roka shall further be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property
to the extent needed to allow Roka to make or have made and continue to market and sell the Panther Instruments under this Supply Agreement, and such, if not already in its possession, shall be promptly delivered to Roka by Gen-Probe, unless
Gen-Probe elects to continue, and continues to perform all of its obligations under this Supply Agreement. 
 9.6. Non-Exclusive
Remedy. Termination of this Supply Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including, without limitation, the Parties’ ability to receive legal damages and/or equitable
relief with respect to any breach of this Supply Agreement, regardless of whether or not such breach was the reason for the termination. 
  

	10.	REPRESENTATIONS AND WARRANTIES 

 10.1. By Both Parties. Each party represents and
warrants to the other that: (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation, and has full corporate power and authority to enter into this Supply Agreement and to carry out the provisions
hereof; (b) it is duly authorized to execute and deliver this Supply Agreement and to perform its obligations hereunder, and the person or persons executing this Supply Agreement on its behalf has been du1y authorized to do so by all requisite
corporate action; and (c) this Supply Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any material agreement, instrument or understanding, oral or Written, to which it is a party or by
which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 
  

	11.	INDEMNIFICATION 

 11.1. Roka Indemnified by Gen-Probe. Gen-Probe hereby agrees to
save, defend and hold the Roka Indemnified Parties harmless from and against any and all demands, liabilities, expenses and/or losses, including reasonable legal expense and attorneys’ fees (collectively, “Losses”) to which any Roka
Indemnified Party may become subject as a result of any Claim by any Third Party to the extent such Losses arise directly or indirectly out of: (a) death or personal injury caused by the design or manufacture of the Panther Instrument (it being
understood that Roka shall not have a claim for indemnification under this subsection (a) where the death or personal injury is caused by or is otherwise the result of an inaccurate test result or other failure of an assay performed on the
Panther Instrument); (b) the breach by Gen-Probe of any material warranty, representation, covenant or agreement made by Gen-Probe in this Supply Agreement; or (c) the negligence or willful misconduct of Gen-Probe; except, in each case, to
the extent such Losses result from the negligence or willful misconduct of any Roka Indemnified Party or the breach by Roka of any material warranty, representation, covenant or agreement made by Roka in this Supply Agreement. 

  
 -21- 

 11.2. Gen-Probe Indemnified by Roka. Roka hereby agrees to save, defend and hold the
Gen-Probe Indemnified Parties harmless from and against any and all Losses to which any Gen-Probe Indemnified Party may become subject as a result of any Claim by any Third Party to the extent such Losses arise directly or indirectly out of:
(a) an inaccurate test result or other failure of an assay performed on the Panther Instrument; (b) the breach by Roka of any material warranty, representation. covenant or agreement made by Roka in this Supply Agreement; or (c) the
negligence or willful misconduct of Roka; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Gen-Probe Indemnified Party or the breach by Gen-Probe of any material warranty, representation.
covenant or agreement made by Gen-Probe in this Supply Agreement. 
 11.3. Prompt Notice Required. No claim for indemnification
hereunder shall be valid unless notice of the matter which may give rise to such claim is given in writing by the indemnitee (the “Indemnitee”) to the Party against whom indemnification may be sought (the “Indemnitor”) as soon as
reasonably practicable after such Indemnitee becomes aware of such claim; provided, however, that the failure to notify the Indemnitor shall not relieve it from any liability that it may have to the Indemnitee otherwise unless the Indemnitor
demonstrates that the defense of the underlying Claim has been materially prejudiced by such failure to provide timely notice. Such notice shall request indemnification and describe the Losses and Claim giving rise to the request for
indemnification, and provide relevant details thereof to the extent then available. The Indemnitor shall notify the Indemnitee no later than thirty (30) days from such notice of its intention to assume the defense of any such Claim. If the
Indemnitor fails to give Indemnitee notice of its intention to defend any such Claim as provided in this Section 11.3, the Indemnitee shall have the right to assume the defense thereof with counsel of its choice, at the Indemnitor’s
expense, and defend, settle or otherwise dispose of such Claim with the consent of the Indemnitor, not to be unreasonably withheld, conditioned or delayed. 

11.4. Indemnitor May Settle. The Indemnitor shall at its expense, have the right to defend, through counsel reasonably satisfactory to
the Indemnitee, any Claim or Losses which is or may be brought in connection with all matters for which indemnification is provided hereunder. In such event, the Indemnitee of the Claim or Losses in question and any successor thereto shall permit
Indemnitor’s counsel and independent auditors, to the extent relevant, full and free access to its books and records and otherwise fully cooperate with the Indemnitor in connection with such Claim or Losses; provided, however, that (i) the
Indemnitee shall have the right fully to participate in such defense at its own expense; (ii) the Indemnitor’s counsel and independent auditors shall not disclose any Confidential Information of the Indemnitee to the Indemnitor without the
Indemnitee’s consent; (iii) access shall only be given to the books and records that are relevant to the Claim or Losses at issue. The defense by the Indemnitor of any such actions shall not be deemed a waiver by the Indemnitor of its
right to assert a claim with respect to the responsibility of the Indemnitee with respect to the Claim or Losses in question. The Indemnitor shall have the right to settle or compromise any Claim against the Indemnitee without the consent of the
Indemnitee provided that the terms thereof: (a) provide for the unconditional release of the Indemnitee; (b) require the payment of compensatory monetary damages by Indemnitor only; and (c) expressly state that neither the fact of
settlement nor the settlement agreement shall constitute, or be construed or interpreted as, an admission by the Indemnitee 

  
 -22- 

 
of any issue, fact, allegation or any other aspect of the Claim being settled. In all other cases, the Indemnitee and Indemnitor must agree to enter into any proposed settlement. No Indemnitee
shall pay or voluntarily permit the determination of any Losses which is subject to any such Claim while the Indemnitor is negotiating the settlement thereof or contesting the matter, except with the prior written consent of the Indemnitor, which
consent shall not be unreasonably withheld, conditioned or delayed. 
 11.5. Assistance. Each Party shall provide all information in
its possession and reasonable assistance to the other Party as necessary to enable the other Party to defend any Claim. The Indemnitee shall provide reasonable cooperation to the Indemnitor in defense of any Claim or Losses, including, but not
limited to, affording complete access to all relevant records. Nothing herein shall prevent the Indemnitee from retaining counsel of its choice, at such Party’s expense, to monitor the defense, trial, or settlement of any matter subject to
indemnification hereunder, and the Indemnitor and its counsel shall reasonably cooperate with such Indemnitee counsel. 
  

	12.	INSURANCE 

 12.1. Amounts. During the Term, each Party shall, at its own expense,
maintain product liability and other insurance appropriate for activities contemplated by this Supply Agreement (or self-insure) in an amount consistent with industry standards. 

 

	13.	GENERAL 

 13.1. Confidentiality. Any information disclosed by one party to the
other Party hereunder pursuant to this Supply Agreement shall be treated as Confidential Information (as defined in the Confidentiality Agreement) and shall be subject to the terms of the Confidentiality Agreement. 

13.2. Dispute Resolution. The Parties hereby acknowledge and agree that any claim, dispute, controversy or disagreement arising under
or relating to the parties’ rights and obligations under this Supply Agreement shall be subject to the Dispute Resolution and Arbitration provisions outlined in Section 6.17 of the Contribution Agreement entered into between the Parties
dated September 10, 2009. 
 13.3. Governing Law. This Supply Agreement and any and all matters arising directly or indirectly
herefrom shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware applicable to agreements made and to be performed entirely in such state, without giving effect to the conflict of law principles
thereof. 
 13.4. Assignment. Except as expressly provided hereunder, neither this Supply Agreement nor any rights or obligations
hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other party (which consent shall not be unreasonably withheld, conditioned or delayed); provided, however, that: 

13.4.1. Either Party may assign this Supply Agreement and its rights and obligations hereunder without the other Party’s consent in
connection with the transfer or sale of all or substantially all of the business or assets of such assigning Party to a Third Party, whether by merger, sale of stock, sale of assets or otherwise; and 

  
 -23- 

 13.4.2. Either Party may assign this Supply Agreement and its rights and obligations hereunder
without the other Party’s consent to an Affiliate of such assigning Party, provided that the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and observance of all such duties and
obligations by such Affiliate. 
 The rights and obligations of the Parties under this Supply Agreement shall be binding upon and inure to the benefit of
the successors and permitted assigns of the Parties. Any assignment not in accordance with this Supply Agreement shall be void. 
 13.5.
Force Majeure. Each Party shall be excused from liability for the failure or delay in performance of any obligation (other than any payment obligation) under this Supply Agreement by reason of any event beyond such party’s reasonable
control, including acts of God, fire, flood, explosion, earthquake, or other natural forces, war, civil unrest, accident, destruction or other casualty, any lack or failure of transportation facilities or any other event similar to those enumerated
above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the party has not caused such event(s) to occur. Notice of a party’s failure or
delay in performance due to force majeure must be given to the other party within 10 days after its occurrence. All delivery dates under this Supply Agreement that have been affected by force majeure shall be tolled for the duration of such force
majeure event(s). In no event shall any party be required to prevent or settle any labor disturbance or dispute. Notwithstanding the foregoing, should the event(s) of force majeure suffered by a party extend beyond a three-month period, the other
party may then terminate this Supply Agreement by written notice to the non-performing party, with the consequences of such termination as set forth in Section 9.4. 

13.6. Limitation on Liability. NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL
OR PUNITIVE DAMAGES IN CONNECTION WITH THIS SUPPLY AGREEMENT; provided, however, that this Section 13.6 shall not be construed to limit (a) either party’s indemnification obligations under Article 11 with respect to Third Party
claims, (b) a party’s obligation to pay the Margin Recovery Amount under Article 6 when due hereunder, or (c) either party’s remedies for breach by the other party of the confidentiality obligations referred to in
Section 13.1. 
 13.7. Entire Agreement; Modification. This Supply Agreement is both a final expression of the parties’
agreement and a complete and exclusive statement with respect to all of its terms. This Supply Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all matters
contained herein, including, without limitation, that certain letter agreement dated as of September 10, 2009 by and between Gen-Probe and Roka regarding “Panther Supply Terms,” which shall be of no further force and effect as of the
Effective Date. This Supply Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Supply Agreement. 

  
 -24- 

 13.8. Non-Waiver. The failure of a Party to insist upon strict performance of any
provision of this Supply Agreement or to exercise any right arising out of this Supply Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other
instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party. 

13.9. Nature of Relationship. In making and performing this Supply Agreement, the Parties are acting, and intend to be treated, as
independent entities and nothing contained herein shall be deemed or implied to create an independent contractor, agency, distributorship, joint venture or -partnership relationship among the Parties hereto. 

13.10. No Third Party Beneficiaries. This Supply Agreement is neither expressly nor impliedly made for the benefit of any party other
than those executing it. 
 13.11. Severability. If, for any reason, any part of this Supply Agreement is adjudicated invalid,
unenforceable or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions of this Supply Agreement. All remaining portions
shall remain in full force and effect as if the original Supply Agreement had been executed without the invalidated, unenforceable or illegal part. 

13.12. Notices. Any notice to be given under this Supply Agreement must be in writing and delivered either in person, by any method of
mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by
proper written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if mailed, five days after the date of postmark; or (c) if delivered by overnight
courier, the next Business Day the overnight courier regularly makes deliveries. 
  

			
	If to Roka:	  	If to Gen-Probe:
		
	 Roka Bioscience, Inc.
 20 Independence
Boulevard, 4th Floor
 Warren, New Jersey 07059
 Attn: Chief
Executive Officer
 Fax: (908) 626-5426
	  	 Gen-Probe Incorporated
 10210 Genetic Center
Drive
 San Diego, California 92121-4362
 Attn: Chief Executive
Officer
 Fax: (858) 410-8637

		
	With a copy to:	  	With a copy to:
		
	 Lowenstein Sandler LLP
 65 Livingston Avenue

Roseland, New Jersey 07068
 Attn: Steven M. Fuerst

Fax: (973) 597-2327
	  	 Gen-Probe Incorporated
 10210 Genetic Center
Drive
 San Diego, CA 92121-4362
 Attn: General Counsel

Fax: (858) 410-8637

  
 -25- 

 13.13. Headings; Ambiguities. The captions or headings of the Sections or other
subdivisions hereof are inserted only as a matter of convenience or for reference and are not part of the agreement of the Parties and shall have no effect on the meaning of the provisions hereof. All references in this Supply Agreement to Sections
or Articles are to Sections or Articles of this Supply Agreement, unless otherwise indicated. Ambiguities and uncertainties in this Supply Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to
have caused the ambiguity or uncertainty to exist. 
 13.14. Counterparts: Facsimile Signature. This Supply Agreement may be executed
in two or more counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. This Supply Agreement may be executed and delivered by facsimile or other electronic
transmission (including .PDF) and upon such delivery the facsimile or other electronically transmitted signature will be deemed to have the same effect as if the original signature had been delivered to the other Party. 

13.15. Survival. The Parties’ respective rights and obligations under the following Sections and Articles (and all associated
definitions) shall survive the termination or expiration of this Supply Agreement: (a) Roka’s payment obligations under Article 6 (to the limited extent any payment obligations accrued thereunder before the termination or expiration of
this Supply Agreement), (b) Sections 9.4 and 9.6, and Articles 7, 11, and 13. 
 [REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK] 

  
 -26- 

 IN WTINESS WHEREOF, the Parties hereto have each caused this Supply Agreement to be executed by
their du1y authorized officers as of the date first above written. 
  

			
	GEN-PROBE INCORPORATED
		
	By:	 	 /s/ Carl W. Hull

	Name:	 	Carl W. Hull
	Title:	 	President and Chief Executive Officer
	
	ROKA BIOSCIENCE, INC.
		
	By:	 	 /s/ Paul G. Thomas

	Name:	 	Paul G. Thomas
	Title:	 	President and Chief Executive Officer

  
 -27- 

 Exhibit A 

Specifications 
 Specifications shall include the
following documents: 
  

	 	•	 	Gen-Probe Performance Acceptance Test Procedure (PATP) 

  

	 	•	 	A description of the field quality acceptance tests, specifications, and criteria used to determine that the Panther Instrument is performing as specified 

 

	 	•	 	Software requirements and specifications for ETF assays 

 Exhibit A 

 Exhibit B 

Assay Integration Documents 
 Gen-Probe shall
supply to Roka the following documents to enable integration of Roka’s NATs on the Panther Instrument: 
  

	 	•	 	Design description of the assay sequence file and the following information for parameters: xml format, function or use of parameter, and whether optional or required. 

 

	 	•	 	A description of Reagent Dispense Verification parameters and limits. 

  

	 	•	 	A description of how to run FlashCheck on the Panther Instrument and acceptance criteria 

  

	 	•	 	A description of how to run SysCheck on the Panther Instrument and acceptance criteria 

  

	 	•	 	A description of system and ETF assay messages and likely causes on the Panther Instrument (may also be known as troubleshooting guide) 

 

	 	•	 	A description of the Laboratory Information Systems interface on the Panther Instrument, including command and response structure and format 

Exhibit B 

 Exhibit C 

Form of Spare Parts Agreement 

Exhibit C 

 Exhibit D 

Schedule of Panther Instrument Training-Related Activities 

The following schedule describes the preliminary training-related activities and deliverables related to the Panther Instrument currently envisioned by
Gen-Probe; however, such training- related activities are still being developed and, as such, Roka acknowledges and agrees that the information set forth in this schedule is preliminary and is subject to
change by Gen-Probe once such training-related activities have been finalized. 
  

	1.	Operator and Training Manuals. Gen-Probe has shared preliminary drafts of operator and training manuals for the Panther Instrument with Roka. Once the final versions of these training manuals are completed, all
future updates and modifications to the manuals by Gen-Probe will be communicated from Gen-Probe’s QA department to Roka’s QA department. It will be the responsibility of Roka to implement any such changes or modifications on the Roka
versions of these manuals. Gen-Probe shall provide electronic (.PDF) versions of the final training manuals to Roka when available, and shall provide electronic (.PDF) versions to Roka of any updated and modified manuals. 

 

	2.	Field Service Engineer (FSE) Training. Gen-Probe currently intends to offer Roka FSE training beginning in the first quarter of 2011. This course for non-TIGRIS trained engineers is expected to last for
approximately 15 Business Days. Gen-Probe provided one FSE training course for 2 Roka employees from January 10- January 28 and has scheduled a second FSE training course for 1 additional Roka employee for March 7- March 25. For
every 12 Panther Instruments ordered by Roka in binding Purchase Orders, Gen-Probe will agree to train 1 additional Roka FSE, provided that Gen-Probe shall not be required to train more than 2 additional Roka FSEs for the remainder of Calendar Year
2011. These training courses will generally be offered by Gen-Probe in its San Diego headquarters location. 

  

	3.	Train-the-Trainer Instruction. Gen-Probe currently intends to offer Roka “train-the- trainer” instructional training in the first quarter of 2011. Gen-Probe shall
provide ‘‘train the trainer” instruction for not more than 2 Roka employees, which will be designed to teach them the skills necessary to operate the Panther Instrument, with the intent that Roka will be able to conduct its own
training classes with respect to the operation of the Panther Instrument in the future. It is anticipated that such training will cover approximately 5 Business Days. This training course is scheduled for the week of February 28- March 4
and will be offered by Gen-Probe in its San Diego headquarters location. 

  

	4.	Train the Customer Training. Gen-Probe currently intends to offer Roka a mock “train the customer” course, where previously trained Roka personnel will conduct the training of internal Roka marketing
staff playing the role of new Panther customers. Gen-Probe personnel will monitor and facilitate this training by providing support and guidance as a “mentor”’ or “coach” of the Roka trainer(s). This course is intended to
help prepare Roka’s personnel to conduct future customer training courses without the presence or support of Gen-Probe. This training course is still being scheduled but will likely be offered by Gen-Probe in its San Diego headquarters
location. 

 Exhibit D 

	5.	Cost of Training Courses. Gen-Probe will provide training services to Roka at a fully burdened rate of $135.00 per hour, plus the cost of materials used during the training courses (including training manuals,
assays and reagents) on a cost plus 20% basis. The student to trainer ratio is generally expected to be 3 students to 1 trainer. If Roka shares a training course with non-Roka representatives, the cost of the training will be reduced on a pro rata
basis (e.g., if a training course is being offered to 2 Roka employees and 1 non-Roka employee, the cost to Roka for such training course would be $90 per hour (2/3rds of $135.00)). 

 

	6.	Field Service Notifications. Roka and Gen-Probe will need to develop a process for handling field service notifications that will be issued by Gen-Probe with respect to the Panther Instrument from time to time.
Additional training may also be required with respect to certain of these field service notifications or as changes are made to the Panther Instrument from time to time. 

Exhibit D 

 Exhibit E 

Panther Instrument Requirements 
  

			
	Environmental Requirements	  	
		
	Ambient Temperature:	  	15 - 30°C
	Relative Humidity:	  	20 - 85%
		
	Electrical Requirements	  	
		
	Electrical Input:	  	100-230 +/- VAC, 50-60Hz, single phase
	Current Input:	  	 Minimum of 15 amp circuit (dedicated)
 20 amp
circuit (dedicated) if used with optional UPS

	Current Draw:	  	 Instrument and ancillaries draw 1,400 watts peak

- 100 VAC circuit draws 14 amps
 - 230 VAC circuit draws 6
amps

		
	Clearance Requirements	  	
		
	PANTHER System:	  	 183 cm (6 ft) minimum width / 244 cm (8 ft) recommended width

198 cm (6.5 ft) vertical clearance
 91.4 cm (3ft) front clearance
for drawer access

 Exhibit E 

 Schedule 5.3 

Reagents and Materials Authorized by Gen-Probe 
  

			
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]

 Schedule 5.3EX-10.26

 Exhibit 10.26 

SECOND AMENDMENT TO 

LICENSE AGREEMENT 
 This
Second Amendment to License Agreement (the “Amendment”) is entered into effective as of June 13, 2014 (the “Amendment Effective Date”) by and between Gen-Probe Incorporated, a Delaware corporation, having a principal place
of business at 10210 Genetic Center Drive, San Diego, California 92121-4362 (“Gen-Probe”), and Roka Bioscience, Inc., a Delaware corporation, having a principal place of business at 20 Independence Boulevard, 4th Floor, Warren, New
Jersey 07059 (“Company”). 
 RECITALS 

WHEREAS, Gen-Probe and Company entered into that certain License Agreement effective as of September 10, 2009, as amended by that
certain First Amendment to License Agreement effective as of May 27, 2011 (as amended, the “License Agreement”); and 

WHEREAS, Gen-Probe and Company wish to amend the License Agreement to modify certain terms of the License Agreement. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 TERMS 

 

	1.	Definitions. All capitalized terms used in this Amendment but not otherwise defined herein will have the respective meanings given to such terms in the License Agreement. 

 

	2.	Amendment of Section 3.1(a). Section 3.1(a) of the License Agreement is hereby amended and restated to read in its entirety as follows: 

3.1(a) Gen-Probe. In addition to the equity issued to Gen-Probe pursuant to the Contribution Agreement, in partial
consideration of the contribution of the Assets under the Contribution Agreement and the grant of the rights by Gen-Probe under Section 2.1, Company shall pay Gen -Probe royalties on Net Sales at the rates set forth on Schedule 3.1 under
the heading “Total Gen-Probe Royalties” for Products for use on CUDA, Panther or Gen -Probe’s Tigris® instrument, as applicable. For the avoidance of doubt, royalties on
Products for use on any other instrument developed or acquired by Company shall be paid at the same rates as set forth on Schedule 3.1 for Products for use on Panther instruments. 

	3.	Addition of Section 3.4. Section 3.4 is hereby added to the License Agreement, and shall read in its entirety as follows: 

3.4 Royalty Reduction Option. 

(a) Option Payment. In consideration for the rights, as set forth in this Section 3.4, for Company to reduce the royalties payable
to Gen-Probe under the Agreement, Company shall pay Gen-Probe, within ten (10) business days after the Amendment Effective Date, the non-creditable, non-refundable sum of two million five hundred thousand dollars ($2,500,000). 

(b) Royalty Reduction Option. Gen-Probe hereby grants to Company the option to reduce the royalties payable to Gen-Probe under this
Agreement in accordance with the terms of this Section 3.4 (“Royalty Reduction Option”) at any time during the period commencing on the Amendment Effective Date through the second anniversary of the Amendment Effective
Date (the “Option Period”). 
 (i) In the event Company successfully completes a firm commitment underwritten public
offering resulting in at least $55.0 million of aggregate net proceeds (net of underwriting discounts and commissions and offering expenses) (such public offering, a “Qualified IPO”), the Royalty Reduction Option shall be
deemed to be automatically exercised contemporaneously with the consummation of the Qualified IPO without any further action by Company or Gen-Probe (an “Automatic Option Exercise”). The date on which the Qualified IPO is
consummated shall be deemed the “Automatic Exercise Date.” 
 (ii) In the event Company successfully completes a firm
commitment underwritten public offering resulting in less than $55.0 million of aggregate net proceeds (net of underwriting discounts and commissions and offering expenses) (such public offering, a “Non-Qualified IPO”),
Company, in its sole discretion, shall have the right to exercise the Royalty Reduction Option (the “Company Option Exercise”). In the event Company elects to exercise the Royalty Reduction Option through the Company Option
Exercise, Company shall provide written notice to Gen-Probe of such election to exercise at least five (5) days prior to the consummation of the Non-Qualified IPO and the Royalty Reduction Option shall be deemed to be exercised
contemporaneously with the consummation of the Non-Qualified IPO without any further action by Company or Gen-Probe. The date on which the Non-Qualified IPO is consummated shall be deemed the “Company Exercise Date.” 

In the event neither a Company Option Exercise nor an Automatic Option Exercise occurs prior to the end of the Option Period, then the royalty
rates set forth in this Agreement shall remain unchanged. In the event a Company Option Exercise or an Automatic Option Exercise occurs during the Option Period, Company shall pay the following consideration to Gen-Probe in the amounts and at the
times specified below, and the royalty rates shall be accordingly reduced as set forth in Section 3.4(c): 

  
 -2- 

 (1) Equity and Cash Consideration. Within ten (10) business days of
the Company Exercise Date or the Automatic Exercise Date, as the case may be, Company shall issue to Gen-Probe: (i) nine million five hundred fifty thousand three hundred and six (9,550,306) shares of common stock (the “Common
Stock”), par value $0.001 per share, of Company (the “Shares”), as adjusted to reflect any stock dividend, stock split, reverse stock split, reclassification, recapitalization or other similar event affecting all of the outstanding
shares of Common Stock on a proportional basis occurring after the Amendment Effective Date and prior to the date of issuance of such Shares; and (ii) a non-creditable, non-refundable cash payment of eight million dollars ($8,000,000).
Notwithstanding the foregoing, Gen-Probe understands and agrees that in connection with a Qualified IPO or a Non-Qualified IPO, Company intends to combine its outstanding shares of Series A common stock and Series B common stock into one class of
common stock of Company. For purposes of this Amendment, all references to Common Stock herein shall be deemed to be such class of common stock authorized by Company at the time of the consummation of a Qualified IPO or a Non-Qualified IPO, as the
case may be. 
 (2) Milestone Payments. Company shall make the following additional non-creditable, non-refundable
milestone payments to Gen- Probe no later than thirty (30) days after the occurrence of the following milestone triggering events: 
  

					
	 	  	 Milestone Triggering Event
	  	 Milestone Payment

			
	 (i)
	  	Company revenues of at least $10.0 million during any twelve month trailing period (including periods prior to the Amendment Effective Date)	  	$3.0 million
			
	 (ii)
	  	Company revenues of at least $25.0 million during any twelve month trailing period (including periods prior to the Amendment Effective Date)	  	$3.0 million
			
	 (iii)
	  	January 1, 2018	  	$5.0 million
			
	 (iv)
	  	January 1, 2020	  	$5.0 million

 (c) Royalty Rate Reduction. In consideration for the equity and cash payments by Company set forth in
Sections 3.4(a) and 3.4(b), the royalty rates payable by Company to Gen-Probe under the Agreement for use of the Gen-Probe Intellectual Property, as set forth in Schedule 3.1, shall be reduced as follows: 

 

					
	 	  	 Rate Reduction Triggering Event
	  	
“Total Company”
Royalty Rate Reduction
(% of Net Sales)

			
	 (i)
	  	 The payment of the consideration set forth in

Section 3.4(b)(1)
	  	 4%

			
	 (ii)
	  	 The payment of the consideration set forth in

Section 3.4(b)(2)(i)
	  	 1%

			
	 (iii)
	  	 The payment of the consideration set forth in

Section 3.4(b)(2)(ii)
	  	 3%

  
 -3- 

 For the avoidance of doubt, the royalty rate reductions in the above table state reductions in
the royalty as percentages of Net Sales and shall be effective from and after Gen- Probe’s receipt of the applicable consideration as set forth in the table above in this Section 3.4(c). For example, after Gen-Probe’s receipt of the
payment of the consideration set forth in Section 3.4(b)(1), the “Total Company” royalty rate payable by Company to Gen-Probe on Company sales of NATs for use on the Panther (Atlas) instrument shall be reduced from 12% of Net Sales to
8.0% of Net Sales. After all three potential royalty rate reductions are applied, the “Total Company” royalty rate payable to Gen-Probe on Company sales of NATs for use on the Panther (Atlas) instrument shall be 4.0% of Net Sales. For the
further avoidance of doubt, the royalty rate reductions contemplated hereby shall apply on a prospective basis only and in no event will Company be eligible to receive any credits for royalties paid or payable with respect to periods prior to the
effectiveness of any royalty rate reduction pursuant to this Agreement. 
 (d) Royalty Reduction Acceleration. Company shall have the
further right in its sole discretion to accelerate the royalty rate reductions specified in Section 3.4(c)(ii) and (iii), by paying the milestone payments specified in Section 3.4(b)(2)(i) and (ii) in advance of the occurrence of the
applicable “Milestone Triggering Event” as set forth in Section 3.4(b)(2). 
  

	4.	Representations and Warranties of Company. Company hereby represents and warrants to Gen-Probe, as of the date hereof and as of the Company Exercise Date or the Automatic Exercise Date, as the case may be, unless
otherwise specified, as follows: 

 (a) Organization and Standing. Company is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware and has full power and authority to own and operate, license or lease its properties, whether tangible or intangible, and conduct its business as currently conducted and as
proposed to be conducted by it and to enter into and perform this Amendment and to carry out the transactions required to be executed by Company contemplated by this Amendment. Company is duly qualified to do business as a foreign corporation and is
in good standing in every jurisdiction in which the failure to so qualify is reasonably likely to have a Material Adverse Effect. “Material Adverse Effect” means a material adverse effect on the business, assets, operations
or condition, financial or otherwise, of Company; provided, however, in no event shall any of the following, either individually or in combination, constitute a Material Adverse Effect: (a) changes in general business or economic conditions in
Company’s industry; (b) any circumstance, change, or effect solely resulting from or arising out of, directly or indirectly, the fact that Company or Gen-Probe (rather than another party) is a party to the transactions contemplated by this
Amendment; or (c) any failure by Company to meet internal projections of forecasts or predictions for any period. 

  
 -4- 

 (b) Authority for Agreement. The execution, delivery and performance by Company of this
Amendment, and the consummation by Company of the transactions contemplated hereby, have been duly authorized by all necessary corporate action. This Amendment has been duly executed and delivered by Company and constitutes the valid and binding
obligation of Company, enforceable against Company in accordance with its terms, except as such enforceability may be limited by (i) bankruptcy, insolvency, receivership, moratorium or other similar laws affecting the enforcement of
creditors’ rights generally and (ii) the availability of equitable remedies may be limited by equitable principles of general applicability. The execution of, and performance of, the transactions contemplated by this Amendment and
compliance with the provisions of this Amendment by Company will not violate any provision of law and will not conflict with or result in any material breach of any of the terms, conditions or provisions of, or constitute a material default under,
or require a consent or waiver under, (x)(i) Company’s Certificate of Incorporation or By-Laws or (ii) any material indenture, lease, agreement (including, without limitation, any loan and security agreement or any other agreement
evidencing indebtedness) or other instrument to which Company is a party or by which it or any of its properties (whether tangible or intangible) is bound, other than those agreements for which Company has received the requisite consent, or
(y) any decree, judgment, order, statute, rule or regulation applicable to Company. 
 (c) Governmental Consents. Except for such
qualifications or filings under applicable securities laws as may be required in connection with the transactions contemplated by this Amendment, no consent, approval, order or authorization of, or registration, qualification, designation,
declaration or filing with, any governmental authority is required on the part of Company in connection with the execution and delivery of this Amendment, and the offer, issuance, sale and delivery of the securities under this Amendment (the
“Securities”), except such filings as shall have been made prior to and shall be effective on and as of Company Exercise Date or the Automatic Exercise Date, as the case may be. Based in part on the representations made by
Gen-Probe in Section 5 hereof, the offer, sale and issuance of the Securities to Gen-Probe will be in compliance with all applicable federal and state securities laws. 

(d) Capitalization. As of the date hereof, Company has a total authorized capitalization consisting of: (a) 142,255,835 shares of
Common Stock, of which (i) 141,963,421 shares have been designated Series A Common Stock, of which (A) 13,906,923 shares are issued and outstanding; (B) 39,680,000 shares have been reserved for issuance upon conversion of
Company’s Series B Preferred Stock, $0.001 par value per share (“Series B Preferred Stock”); (C) 12,090,672 shares have been reserved for issuance upon conversion of Company’s Series C Preferred Stock, $0.001
par value per share (“Series C Preferred Stock”); (D) 33,634,669 shares have been reserved for issuance upon conversion of Company’s Series D Preferred Stock, $0.001 par value per share (the “Series D
Preferred Stock”); (E) 33,601,367 shares have been reserved for issuance upon conversion of Company’s Series E Preferred Stock, $0.001 par value per share (“Series E Preferred Stock”);
(F) 2,480,000 shares have been reserved for issuance upon exercise of outstanding warrants to purchase shares of Series B Preferred Stock; (G) 666,666 shares have been reserved for issuance upon exercise of warrants to purchase shares of
Series E Preferred Stock; and (H) 9,049,790 shares have been reserved for issuance under Company’s 2009 Equity Incentive Plan, as amended (the “Plan”), and (ii) 292,414 shares have been designated Series B
Common Stock, $0.001 par value per share, of which (A) 34,569 are issued and outstanding, and (B) 257,845 are reserved for issuance upon conversion of Company’s Series A Common Stock; and (b) 117,884,018 shares of Preferred
Stock, $0.001 par value per share (the “Preferred Stock”), of which (i) 39,680,000 shares have been designated Series B Preferred Stock, 37,200,000 of which are issued and outstanding and 2,480,000 of which are reserved
for issuance upon exercise of outstanding warrants; (ii) 12,090,672 shares have been designated Series C Preferred Stock, all of which are issued and outstanding; (iii) 32,511,979 shares have been designated Series D Preferred Stock, all
of which are issued and outstanding; and (iv) 33,601,367 shares have been designated Series E Preferred Stock, 32,934,700 of which are issued and outstanding. All of the issued and outstanding shares of Company’s capital stock have been
duly authorized and validly issued and are fully paid and non-assessable, and were issued in accordance with the registration or qualification provisions of the Securities Act of 1933, as amended (the “Securities Act”).
Except as set forth in Schedule 4 or as otherwise provided in this Agreement, (1) no subscription, warrant, option, convertible security or other right (contingent or otherwise) to purchase or acquire any shares of capital stock of
Company is authorized or outstanding, (2) Company has no obligation (contingent or otherwise) to issue any subscription, warrant, option, convertible security or other such right or to issue or distribute to holders of any shares of its capital
stock any evidences of indebtedness or assets of Company, and (3) Company has no obligation (contingent or otherwise) to purchase, redeem or otherwise acquire any shares of its capital stock or any interest therein or to pay any dividend or
make any other distribution in respect thereof. The issuance and sale of the Shares and all other outstanding shares of capital stock of Company is in compliance with any and all applicable rights of first refusal, preemptive rights or similar
rights of any third party. 

  
 -5- 

 (e) Issuance of Securities. The issuance, sale and delivery of the Securities in
accordance with this Amendment have been duly authorized by all necessary corporate action on the part of Company. Upon the completion of the Qualified IPO or Non-Qualified IPO, as the case may be, all such shares shall have been duly reserved for
issuance. The Shares sold and delivered against payment therefor in accordance with the provisions of this Amendment will be duly and validly issued, fully paid and non-assessable and free of restrictions on transfer other than restrictions on
transfer under applicable federal and state securities laws and liens or encumbrances created by or imposed by Gen-Probe. 
 (f)
Brokers. Company has not retained any finder or broker in connection with the transactions contemplated by this Amendment and Company separately agrees to indemnify and save Gen-Probe harmless from and against any and all claims, liabilities
or obligations with respect to brokerage or finders’ fees or commissions in connection with the transactions contemplated by this Amendment asserted by any person on the basis of any agreement, statement or representation alleged to have been
made by Company. 
  

	5.	Representations and Warranties of Gen-Probe. Gen-Probe hereby represents and warrants to Company, as of the date hereof and as of the Company Option Exercise and the Automatic Option Exercise, as the case may be,
as follows: 

 (a) Accredited Investor. Gen-Probe is an “accredited investor” within the meaning of Rule
501(a) under the Securities Act, and understands that Company has relied upon its being an accredited investor in deciding to proceed with the transactions contemplated hereby, and in ascertaining the requirements of law applicable to the issuance
and sale of the Shares being purchased hereby. Gen-Probe’s financial condition is such that Gen-Probe is able to bear all economic risks of investment in the Securities, including a complete loss of Gen-Probe’s investments therein.
Gen-Probe acknowledges that Company has provided it with adequate access to financial and other information concerning Company as requested and that it has had the opportunity to ask questions of and receive answers from Company concerning the
transactions contemplated under this Amendment and to obtain therefrom any additional information necessary to make an informed decision regarding an investment in Company. 

  
 -6- 

 (b) Investment. Gen-Probe is acquiring the Securities for its own account for investment
and not with a view to, or for sale in connection with, any distribution thereof, nor with any present intention of distributing or selling the same; and, except as contemplated by this Amendment, Gen-Probe has no present or contemplated agreement,
undertaking, arrangement, obligation, indebtedness or commitment providing for the disposition thereof. 
 (c) Authority. Gen-Probe
has full power and authority to enter into and to perform its obligations under this Amendment in accordance with its terms. Gen-Probe represents that it has not been organized, reorganized or recapitalized specifically for the purpose of investing
in Company. This Amendment has been duly executed and delivered by Gen-Probe and constitutes the valid and binding obligation of Gen-Probe, enforceable against Gen-Probe in accordance with its terms, except as such enforceability may be limited by
(i) bankruptcy, insolvency, receivership, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and (ii) the availability of equitable remedies may be limited by equitable principles of general
applicability. The execution of, and performance of, the transactions contemplated by this Amendment and compliance with the provisions hereof by Gen-Probe will not, to its knowledge, violate any provision of law and, if applicable, will not
conflict with or result in any material breach of any of the terms, conditions or provisions of, or constitute a material default under, or require a consent or waiver under, its organizational documents (if any, and each as amended to date and as
in effect as of the date hereof) or any material indenture, lease, agreement or other instrument to which Gen-Probe is a party or by which it or any of its properties (whether tangible or intangible) is bound, or any decree, judgment, order,
statute, rule or regulation applicable to Gen-Probe. 
 (d) Unregistered Securities. Gen-Probe acknowledges and agrees that the
Securities, and any shares issuable upon conversion or exercise thereof, must be held indefinitely until such time as they are subsequently registered under the Securities Act or an exemption from such registration is available. Gen-Probe has been
advised or is aware of the provisions of Rule 144 promulgated under the Securities Act, which currently permits limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions. 

(e) Brokers. Gen-Probe has not retained any finder or broker in connection with the transactions contemplated by this Amendment and
Gen-Probe separately agrees to indemnify and save Company harmless from and against any and all claims, liabilities or obligations with respect to brokerage or finders’ fees or commissions in connection with the transactions contemplated by
this Amendment asserted by any person on the basis of any agreement, statement or representation alleged to have been made by Gen-Probe. 

  
 -7- 

	6.	Lock-Up. Gen-Probe agrees that for a period (the “Lock-Up Period”) beginning on the date hereof and ending on, and including, the date that is one hundred eighty (180) days after the
first to occur of the Company Exercise Date or the Automatic Exercise Date, Gen-Probe will not, without the prior written consent of Company, (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase
or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act with respect to,
any of the Shares or any other securities of Company that are substantially similar to the Shares, or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing, (ii) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of Common Stock or any other securities of Company that are substantially similar to Common Stock, or any securities
convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing, whether any such transaction is to be settled by delivery of Common Stock or such other securities, in cash or otherwise or
(iii) publicly announce an intention to effect any transaction specified in clause (i) or (ii). 

  

	7.	No Other Amendments. Except as expressly provided in this Amendment, the License Agreement is, and shall continue to be, in full force and effect in accordance with its terms, without further amendment thereto.

  

	8.	Counterparts. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument.
Facsimile signatures are deemed equivalent to original signatures for purposes of this Amendment. 

  

	9.	Governing Law. This Amendment shall be governed by and construed in accordance with the internal laws of the State of California without giving effect to any choice of law rule that would cause the application of
the laws of any jurisdiction other than the internal laws of the State of California to the rights and duties of the parties. This Amendment is effective on the Amendment Effective Date. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 -8- 

 IN WITNESS WHEREOF, the parties to this Amendment, having read and understood the foregoing,
acknowledge their legally binding acceptance of this Amendment by the signatures of their duly authorized representatives below. 
  

									
	GEN-PROBE INCORPORATED	 		 	ROKA BIOSCIENCE, INC.
					
	By:	 	 /s/ Robert W. McMahon
	 		 	By:	 	 /s/ Paul G. Thomas

	Name:	 	Robert W. McMahon	 		 	Name:	 	Paul G. Thomas
	Title:	 	Chief Financial Officer	 		 	Title:	 	Chief Executive Officer

  
 -9- 

 Schedule 4 

 

					
	 Securities Outstanding or Authorized for Issuance
	  	Number of Shares	 
	 Series A Common Stock Options Outstanding
	  	 	7,194,580	  
	 Remaining Shares of Series A Common Stock Authorized to be issued under the 2009 Equity Compensation Plan
	  	 	2,686,705	  
	 Series B Preferred Stock Warrants outstanding
	  	 	2,480,000	  
	 Series E Preferred Stock Warrants outstanding
	  	 	509,804	  
	 Series E Preferred Stock Warrants issuable upon borrowings under 3rd tranche of loan agreements
	  	 	156,863	  
	 Additional Shares of Series B Common Stock Authorized
	  	 	257,845

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]